A paradigm for single nucleotide polymorphism analysis: The case of the acetylcholinesterase gene

Human Mutation

Volumn 24, Issue 5, 2004, Pages 408-416

  Hasin, Yehudit ^a   Avidan, Nili ^a   Bercovich, Dani ^b   Korczyn, Amos ^c   Silman, Israel ^a   Beckmann, Jacques S ^a,d,e   Sussman, Joel L ^a,e  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Department of Molecular Genetics ^*  (Israel)

Author keywords

Acetylcholinesterase; ACHE; Adverse drug reaction; Alzheimer disease; SNP

Indexed keywords

ACETYLCHOLINESTERASE;

AFRICAN AMERICAN; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARAB; ARTICLE; CATALYSIS; CONTROLLED STUDY; ETHNIC GROUP; GENE SEQUENCE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; JEW; NUCLEOTIDE SEQUENCE; POPULATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; ACETYLCHOLINESTERASE; AMINO ACID SEQUENCE; BASE COMPOSITION; BASE SEQUENCE; CATALYSIS; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; EXONS; GENE FREQUENCY; HAPLOTYPES; HUMANS; INTRONS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION;

EID: 8144226101     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20106     Document Type: Article

References (40)

1. Bartels CF, Zelinski T, Lockridge O. 1993. Mutation at codon 322 in the Human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet 52:928-936.
2. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. 2001. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279-284.
3. Bercovich D, Beaudet AL. 2003. Denaturing high-performance liquid chromatography for the detection of mutations and polymorphisms in UBE3A. Genet Test 7:189-194.
4. Bonfield JK, Smith K, Staden R. 1995. A new DNA sequence assembly program. Nucleic Acids Res 23:4992-4999.
5. Bourne Y, Taylor P, Bougis PE, Marchot P. 1999. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J Biol Chem 274:2963-2970.
6. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. 2003. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 17:214-222.
7. Darvesh S, Hopkins DA, Geula C. 2003. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131-138.
8. Duetsch G, Illig T, Loesgen S, Rohde K, Klopp N, Herbon N, Gohlke H, Altmueller J, Wjst M. 2002. STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study. Hum Mol Genet 11:613-621.
9. Ehrlich G, Ginzberg D, Loewenstein Y, Glick D, Kerem B, Ben-Ari S, Zakut H, Soreq H. 1994. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from trans-Caucasian Georgia and from Europe. Genomics 22:288-295.
10. Escary JL, Bottius E, Prince N, Reyes C, Fiawoumo Y, Caloustian C, Bruls T, Fujiyama A, Cooper RS, Adeyemo AA, Lathrop GM, Weissenbach J, Gyapay G, Foglio M, Beckmann JS. 2000. A first high-density map of 981 biallelic markers on human chromosome 14. Genomics 70:153-164.
11. Felder CE, Botti SA, Lifson S, Silman I, Sussman JL. 1997. External and internal electrostatic potentials of cholinesterase models. J Mol Graph Model 15:318-327.
12. Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JH, Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. 2000. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 67:881-900.
13. Giacobini E. 2000. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz. p 181-226.
14. Greenblatt HM, Dvir H, Silman I, Sussman JL. 2003. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J Mol Neurosci 20:369-383.
15. Kawashima K, Fujii T. 2000. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 86:29-48.
16. Knowles JW, Erickson LM, Guy VK, Sigel CS, Wilder JC, Maeda N. 2003. Common variations in noncoding regions of the human natriuretic peptide receptor A gene have quantitative effects. Hum Genet 112:62-70.
17. Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, Kronman C, Barak D, Ariel N, Shafferman A, and others. 2000. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr 56:1385-1394.
18. Lambert JC, Goumidi L, Vrieze FW, Frigard B, Harris JM, Cummings A, Coates J, Pasquier F, Cottel D, Gaillac M, St Clair D, Mann DM, Hardy J, Lendon CL, Amouyel P, Chartier-Harlin MC. 2000. The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Hum Mol Genet 9:2275-2280.
19. Lev-Lehman E, Deutsch V, Eldor A, Soreq H. 1997. Immature human megakaryocytes produce nuclear-associated acetylcholinesterase. Blood 89:3644-3653.
20. Li Y, Camp S, Rachinsky TL, Getman D, Taylor P. 1991. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. J Biol Chem 266:23083-23090.
21. Massoulié J, Anselmet A, Bon S, Krejci E, Legay C, Morel N, Simon S. 1999. The polymorphism of acetylcholinesterase: posttranslational processing, quaternary associations and localization. Chem Biol Interact 119-120:29-42.
22. Michaelis ML. 2003. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 304:897-904.
23. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura J, Irahara N, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. 2003. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 39:2531-2537.
24. Richard I, Beckmann JS. 1995. How neutral are synonymous codon mutations? Nat Genet 10:259.
25. Ripoll DR, Faerman CH, Axelsen PH, Silman I, Sussman JL. 1993. An electrostatic mechanism for substrate guidance down the aromatic gorge of acetylcholinesterase. Proc Natl Acad Sci USA 90:5128-5132.
26. Scarpini E, Schaltens P, Feldman H. 2003. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2:539-547.
27. Seidman S, Sternfeld M, Ben Aziz-Aloya R, Timberg R, Kaufer-Nachum D, Soreq H. 1995. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3′-terminal exons. Mol Cell Biol 15:2993-3002.
28. Shapira M, Tur-Kaspa I, Bosgraaf L, Livni N, Grant AD, Grisaru D, Korner M, Ebstein RP, Soreq H. 2000. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet 9:1273-1281.
29. Silman I, Sussman JL. 2000. Structural studies on acetylcholinesterase. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz. p 9-25.
30. Soreq H, Seidman S. 2001. Acetylcholinesterase - new roles for an old actor. Nat Rev Neurosci 2:294-302.
31. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
32. Sternfeld M, Ming G, Song H, Sela K, Timberg R, Poo M, Soreq H. 1998. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini. J Neurosci 18:1240-1249.
33. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. 1991. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253:872-879.
34. Talesa VN. 2001. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 122:1961-1969.
35. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Hewlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511.
36. Vitkup D, Sander C, Church GM. 2003. The amino-acid mutational spectrum of human genetic disease. Genome Biol 4:R72.
37. Wang Z, Moult J. 2001. SNPs, protein structure, and disease. Hum Mutat 17:263-270.
38. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH, Lockridge O. 2000. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 293:896-902.
39. Xie W, Wilder PJ, Stribley J, Chatonnet A, Rizzino A, Taylor P, Hinrichs SH, Lockridge O. 1999. Knockout of one acetylcholinesterase allele in the mouse. Chem Biol Interact 119-120:289-299.
40. Yaron Y, Ben Zeev B, Shomrat R, Bercovich D, Naiman T, Orr-Urtreger A. 2002. MECP2 mutations in Israel: implications for molecular analysis, genetic counseling, and prenatal diagnosis in Rett syndrome. Hum Mutat 20:323-324.